Altimmune, Inc. (Nasdaq: ALT) is making waves in the biopharmaceutical sector today, with its stock surging by a remarkable +27.42% to $9.36 in Tuesday’s trading session, as of 12:34 PM EDT. This sudden spike has attracted considerable attention, with 13.62 million shares traded so far—far surpassing its typical trading volume of 2.17 million shares. What’s behind this surge, and why is Altimmune one of the trending stocks today? Let’s break it down.
Sponsored
Analyst Rating & Price Target Boost
One of the most significant drivers of today’s rally is the recent “Buy” rating issued by UBS. On November 12, 2024, UBS initiated coverage of Altimmune with an optimistic outlook, setting a price target of $26—more than double its current price of $9.36. This enthusiastic recommendation is likely a key catalyst for the surge, sparking investor interest in the clinical-stage biopharmaceutical company.
UBS’s rating aligns with several recent positive developments at Altimmune, including advancements in their pipeline and key regulatory milestones. This surge in interest comes as investors are beginning to recognize the potential of Altimmune’s pipeline, particularly its promising pemvidutide program, which is positioned for crucial trials in the near future.
For a deeper dive into the analyst rating, you can explore more about the UBS report here.
Altimmune’s Business and Product Portfolio
Altimmune, Inc. is a clinical-stage biopharmaceutical company that focuses on developing innovative therapies for infectious diseases, metabolic disorders, and other conditions requiring novel treatments. The company has made significant strides in its research and development efforts, particularly in the areas of obesity, non-alcoholic steatohepatitis (NASH), and infectious diseases.
At the core of Altimmune’s pipeline is pemvidutide, an investigational peptide being studied for its potential to treat obesity and metabolic conditions. Pemvidutide has demonstrated promising results in early trials and has the potential to be a game-changer in the treatment of obesity and its associated co-morbidities.
Here’s a closer look at Altimmune’s focus areas:
- Pemvidutide: Currently in Phase 2b trials for MASH (Metabolic Associated Steatohepatitis), Altimmune is also gearing up for Phase 3 trials targeting obesity. The company has made significant progress, including reaching an agreement with the FDA on the design of its pivotal studies for obesity, which are set to evaluate weight loss and improvements in co-morbidities like elevated lipids and liver fat.
- Infectious Disease Vaccines: Altimmune has a rich history in developing vaccines, with a focus on needle-free delivery systems. Their Nasal COVID-19 vaccine is an example of how the company is innovating in the field of immunization, delivering vaccines via the nasal route, which could offer greater convenience and potentially improved immune responses.
The company is also involved in other discovery projects that could drive future growth, with research activities extending across various therapeutic areas.
Financial Health and Recent Milestones
Altimmune’s financials for the third quarter of 2024 reflect a company that is investing heavily in its R&D efforts, with total research and development expenses coming in at $19.8 million for the quarter. This is slightly up from the $18.4 million recorded during the same period in 2023, highlighting the company’s ongoing commitment to advancing its pipeline.
While the company posted a net loss of $22.8 million (or $0.32 per share) for the quarter, the loss is relatively consistent with the previous year’s $20.7 million loss. Importantly, Altimmune remains well-capitalized with $139.4 million in cash, cash equivalents, and short-term investments as of September 30, 2024, which should provide the company with ample runway to continue its critical clinical trials and operations.
In a notable corporate update, the company appointed Greg Weaver as the new Chief Financial Officer (CFO) on November 11, 2024. Weaver brings decades of experience in the life sciences sector, which could be a signal of Altimmune’s intentions to strengthen its financial management and strategy as it moves forward with its pipeline.
Stock Performance: YTD Comparison
While Altimmune’s stock has faced challenges in 2024, with a year-to-date (YTD) performance of -18.04%, the company’s latest developments have investors hopeful for a turnaround. In contrast, the S&P 500 has had a much stronger performance in 2024, up by +25.37% as of November 12.
Altimmune’s underperformance relative to the broader market could be seen as a potential buying opportunity, especially in light of the recent analyst upgrade and the company’s positive pipeline developments. The stock’s volatility is typical for clinical-stage biotech companies, which can experience significant price swings based on trial results, regulatory updates, and market sentiment.
What’s Next for Altimmune?
Altimmune’s journey is just beginning. With key milestones ahead, such as the top-line results for the Phase 2b IMPACT trial of pemvidutide expected in the second quarter of 2025 and Phase 3 obesity trials poised to begin, investors are closely watching for further updates. If pemvidutide lives up to its promise, Altimmune could see a substantial increase in value, aligning with the $26 price target set by UBS.
Moreover, the company’s ongoing focus on innovative treatments in obesity, NASH, and infectious diseases places it in a strong position to capture significant market share in these high-demand therapeutic areas. The market is clearly paying attention, with the surge in trading volume and price reflecting growing investor confidence in Altimmune’s future.
Conclusion
Altimmune, Inc. is a company that could be on the brink of significant breakthroughs. With strong backing from analysts, an encouraging pipeline, and a robust financial position, the company is attracting considerable investor interest. However, like many biopharmaceutical companies, its future success hinges on the results of ongoing clinical trials and regulatory approvals. As such, investors will want to stay tuned for upcoming updates, particularly in the first half of 2025, when pivotal trial data for pemvidutide is expected to be released.
